Allegiance's CinGx for Treatment and Prevention of Memory Loss Achieves Major Milestone
08 Octobre 2011 - 11:08AM
PR Newswire (Canada)
TORONTO, Oct. 11, 2011 /CNW/ - Allegiance Equity Corporation .
Health Canada's acceptance of Master Ingredient File for CinGx
marks a major new milestone for Allegiance. "The Acceptance for the
filing of the Master Ingredient File with Health Canada by
our partners Nealanders International Inc and Dicentra two world
class companies is a major accomplishment for Allegiance and CinGx,
remarked David Solomon, CEO of Allegiance.( ) CinGx(TM) a
Revolution in Functional Food CinGx(TM) is an all natural patented
blend of Panax Ginseng and Cinnamon Bark Extract that reduces blood
glucose levels and improved brain function. This amazing flavorless
powder can easily be incorporated into many different foods and
beverage applications CinGx(tm) has the benefits of -- Reduces
blood sugar -- Reduces mental fatigue -- And enhances physical
capacity and performance With the filing of the Master Ingredient
File with Health Canada North American manufacturers now have a new
and exciting way to bring consumers revolutionary new health
benefits. This extensive filing on safety and evidence supports the
claims for new and exciting health claims. Dicentra assisted
Nealanders in preparing the necessary regulatory documentation for
CinGx(TM) Dicentra is a leading international scientific and
regulatory consulting firm with specialized expertise in the areas
of natural health products, dietary supplements, OTCs, foods and
cosmetics. Dicentra is directly involved in the successful
development of hundreds of leading products in North America and
throughout the world. CinGx(TM) a platform technology with a
multitude of mass market applications Similar companies in the same
industry such as Danon introduced their probiotic yogurts in 2006
and in 2010 they had increased revenues by several billion annually
worldwide. Red Bull was introduced in 1989, creating an entirely
new category of beverage and as of 2010, their sales had exceeded
$4 billion CinGx(TM)( )with far greater and substantial health
benefits and more diverse product applications represent a similar
if not greater opportunity. "We are extremely fortunate and
grateful to have Nealanders as a partner, you couldn't have asked
for a better fit for Allegiance. They are poised to market
CinGx(TM) to their clients for placement in a variety of foods and
beverages," stated David Solomon, President of Allegiance.
Nealanders has completed regulatory documentation for compliance
with Health Canada and the FDA requirements to facilitate marketing
CinGx(TM) to its clients. They have formulated foods and beverages
in several categories containing CinGx(TM) for presentation to
major food manufacturers where Nealanders has established
relationships. "I am very excited about moving forward with this
revolutionary new additive CinGxT," says Steve Owen, VP Sourcing,
Product Development GM - Ontario. ABOUT NEALANDERS Nealanders is a
full service producer and distributor of food ingredients,
supplying the broadest range of complementary ingredients to a
large and diversified customer base. Nealanders is also the
exclusive Canadian distributor for several of the world's
pre-eminent ingredient manufacturers, and is the largest co-packer
of instant oatmeal in Canada. Allegiance Grants Directors Options
Allegiance Equity Corporation announces that it has awarded 564,450
share purchase options ("the Awarded Options") to directors and
senior management to buy common shares in the Company. The Awarded
Options include the grants of 112,890 common shares at $0.55 per
share to the directors of the Company namely David Solomon.Marilyn
Bloovol, Donald Stott, Dr Melvin Goldberg, and Philip Bookalam. The
options are exercisable up to and including September 24, 2016.
ABOUT ALLEGIANCE Allegiance targets billion dollar markets having
clearly identified product deficiencies and dissatisfied patients
who suffer widespread diseases and conditions including diabetes,
cholesterol, Alzheimer`s and Dementia and arthritis. Allegiance's
strategy utilizes leading-edge scientific technology to create
valuable, proprietary and effective natural treatments, recognized
as safe and effective by North American regulatory authorities, at
a fraction of the cost and time it takes to develop a prescription
drug. Allegiance then obtains patents and regulatory approvals.
Additional information relevant to the Company's activities,
including the Company's press releases can be found on SEDAR at
www.sedar.com. The TSX Venture Exchange has not reviewed and does
not accept responsibility FOR THE ADEQUACY OR ACCURACY FOR THIS
PRESS RELEASE, WHICH HAS BEEN PREPARED BY MANAGEMENT. Allegiance
Equity Corporation CONTACT: Allegiance Equity Corporation David
Solomon President (416) 6301221Email dsolomon79@gmail.com
Copyright
(TSXV:ANQ)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
(TSXV:ANQ)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about (TSX Venture Exchange): 0 recent articles
Plus d'articles sur Allegiance Equity Corp